A multinational double blind placebo-controlled, parallel group study to evaluate the efficacy and safety of CCX282B in subjects with moderate to severe Crohn's disease.

Trial Profile

A multinational double blind placebo-controlled, parallel group study to evaluate the efficacy and safety of CCX282B in subjects with moderate to severe Crohn's disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2014

At a glance

  • Drugs Vercirnon (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROTECT-1
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Oct 2014 Results published in a ChemoCentryx media release.
    • 29 Jun 2012 Planned number of patients changed from 423 to 598 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top